Serotonin receptor agonist

Bright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond

Retrieved on: 
Friday, June 11, 2021
Branches of biology, Neuroscience, Neurotransmitters, Psychedelic drugs, Hallucinations, Entheogens, Serotonin receptor agonist, Serotonin, Psilocybin, Serotonergic

The presentation will be webcast beginning at the aforementioned time and available for 7 days thereafter using the link provided above.

Key Points: 
  • The presentation will be webcast beginning at the aforementioned time and available for 7 days thereafter using the link provided above.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Bright Minds Biosciences to Present at the 2021 LD Micro Invitational XI

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Neuroscience, Neurotransmitters, Psychedelic drugs, Hallucinations, Entheogens, Serotonin receptor agonist, Serotonin, Psilocybin, Serotonergic

The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.

Key Points: 
  • The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Bright Minds Biosciences to Present at the Stifel GMP Healthcare Conference - Healthcare Psychedelics: Addressing the Global Mental Health Crisis

Retrieved on: 
Wednesday, March 10, 2021
Branches of biology, Neuroscience, Neurotransmitters, Psychedelic drugs, Hallucinations, Entheogens, Serotonin receptor agonist, Serotonin, Psilocybin, Serotonergic

The presentation will be webcast live at the aforementioned time and available for one week thereafter using the link provided above.

Key Points: 
  • The presentation will be webcast live at the aforementioned time and available for one week thereafter using the link provided above.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Bright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of Units

Retrieved on: 
Tuesday, February 23, 2021
Bright, Serotonin receptor agonist

VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (Bright Minds or the Company) announces the pricing of its previously announced underwritten marketed offering (the Offering) of an aggregate of 3,303,000 units of the Company (the Units) at a price of $7.57 per Unit for gross proceeds to the Company of approximately $25,000,000.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (Bright Minds or the Company) announces the pricing of its previously announced underwritten marketed offering (the Offering) of an aggregate of 3,303,000 units of the Company (the Units) at a price of $7.57 per Unit for gross proceeds to the Company of approximately $25,000,000.
  • Bright Minds is a pre-clinical biosciences company with a portfolio of compounds designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds was selected to participate in two National Institutes of Health (NIH) Programs.
  • These NIH collaborations are evaluating Bright Minds serotonin agonists for therapeutic potential in pain and in epilepsy.

Bright Minds Biosciences Inc. Announces Marketed Public Offering

Retrieved on: 
Monday, February 22, 2021
Serotonin receptor agonist, Bright

VANCOUVER, British Columbia, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (Bright Minds or the Company) announces that it has commenced an underwritten marketed public offering (the Offering) of units of the Company (the Units).

Key Points: 
  • VANCOUVER, British Columbia, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (Bright Minds or the Company) announces that it has commenced an underwritten marketed public offering (the Offering) of units of the Company (the Units).
  • Bright Minds is a pre-clinical biosciences company with a portfolio of compounds designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds was selected to participate in two National Institutes of Health (NIH) Programs.
  • These NIH collaborations are evaluating Bright Minds serotonin agonists for therapeutic potential in pain and in epilepsy.

Bright Minds Biosciences Announces Listing on Canadian Stock Exchange

Retrieved on: 
Friday, February 5, 2021
Branches of biology, Neuroscience, Neurotransmitters, Hallucinations, Psychedelic drugs, Entheogens, Serotonin receptor agonist, Serotonin, Psilocybin, Serotonergic, Serotonergic psychedelic

Bright Minds is focused on modern-day drug design and aims to improve on first-generation psychedelics by creating drugs that are selective serotonin agonists.

Key Points: 
  • Bright Minds is focused on modern-day drug design and aims to improve on first-generation psychedelics by creating drugs that are selective serotonin agonists.
  • Today marks a significant milestone for Bright Minds, as we officially become a publicly traded company.
  • Bright Minds is a pre-clinical biosciences company with a portfolio of compounds designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Eleusis Announces Published Research on Potential of Serotonin 2A Receptor Agonists to Impact Inflammation

Retrieved on: 
Tuesday, September 17, 2019
Science, Other Science, Pharmaceutical, Research, Health, Clinical trials, Drugs, Receptor agonists, Neurochemistry, 5-HT2A receptor, Biology of bipolar disorder, Serotonin, Serotonin receptor agonist, Ro60-0175

Eleusis , a clinical stage life science company established to develop the therapeutic potential of serotonin 2A receptor (5-HT2A) agonists, also known as psychedelics, today announced new research published in Scientific Reports demonstrating the anti-inflammatory properties of 5-HT2A agonists in a translational model of cardiovascular disease (CVD).

Key Points: 
  • Eleusis , a clinical stage life science company established to develop the therapeutic potential of serotonin 2A receptor (5-HT2A) agonists, also known as psychedelics, today announced new research published in Scientific Reports demonstrating the anti-inflammatory properties of 5-HT2A agonists in a translational model of cardiovascular disease (CVD).
  • The publication presents data that demonstrate 5-HT2A receptor agonists are efficacious in addressing the prevention of inflammation in a disease context and that they appear to provide added therapeutic benefits beyond blocking inflammation.
  • Our research provides a solid foundation to advance the clinical development of 5-HT2A receptor agonists to address unmet needs in chronic inflammatory diseases.
  • These results further validate our proprietary pipeline of 5-HT2A agonists and their therapeutic potential to treat inflammation, said Shlomi Raz, Chairman and Founder of Eleusis.